MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/07853890.2022.2069280

Медицинская библиотека · Annals of medicine · 2022

Outcomes of adolescents and young adults with chronic-phase chronic myeloid leukaemia treated with tyrosine kinase inhibitors.

Nishiyama-Fujita Yuriko, Nakazato Tomonori, Iriyama Noriyoshi, Tokuhira Michihide, Ishikawa Maho, Sato Eriko, Takaku Tomoiku, Sugimoto Keiji, Fujita Hiroyuki, Fujioka Isao, Tsuchiya Shun, Kimura Yuta, Iwanaga Eisaku, Komatsu Norio, Asou Norio, Kizaki Masahiro, Hatta Yoshihiro, Kawaguchi Tatsuya

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

INTRODUCTION

Few studies have reported the outcomes of adolescents and young adults (AYAs) with chronic-phase chronic myeloid leukaemia (CML-CP) on tyrosine kinase inhibitors (TKIs).

MATERIALS AND

METHODS

We retrospectively analysed the clinical features, treatment response, and long-term outcomes of 42 AYA patients, in comparison to older patients. The initial therapies of AYA patients between 2001 and 2016 included imatinib (n = 24), dasatinib (n = 13) and nilotinib (n = 5).

RESULTS

In AYA patients, the peripheral blood (PB) white blood cell count and percentage of blasts at the diagnosis were significantly higher, haemoglobin levels were lower and the spleen size was larger. The major molecular response (MMR), event-free survival (EFS) and overall survival (OS) rates were comparable. A sub-analysis comparing imatinib to second-generation TKIs as the initial therapy also showed that their prognosis was comparable.

DISCUSSION: In conclusion, the tumour burden at the diagnosis of CML-CP is higher in AYA patients; however, their prognosis was not worse in comparison to older patients treated with TKIs. KEY MESSAGESFew studies have reported the outcomes of adolescents and young adults (AYAs) with chronic-phase chronic myeloid leukaemia (CML-CP) on tyrosine kinase inhibitors (TKIs). This study showed the tumour burden at the diagnosis of CML-CP is higher in AYA pa tients; however, their prognosis was not worse in comparison to older patients treated with TKIs. Understanding the biological and non-biological features of AYA patients with CML-CP on TKI therapy is essential for better management and to improve the outcomes.

Для цитирования: Nishiyama-Fujita Yuriko, Nakazato Tomonori, Iriyama Noriyoshi, Tokuhira Michihide, Ishikawa Maho, Sato Eriko, Takaku Tomoiku, Sugimoto Keiji, Fujita Hiroyuki, Fujioka Isao, Tsuchiya Shun, Kimura Yuta, Iwanaga Eisaku, Komatsu Norio, Asou Norio, Kizaki Masahiro, Hatta Yoshihiro, Kawaguchi Tatsuya. Outcomes of adolescents and young adults with chronic-phase chronic myeloid leukaemia treated with tyrosine kinase inhibitors.. Annals of medicine. 2022. DOI: 10.1080/07853890.2022.2069280.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.